PTEN and prostate carcinoma: The PTEN tumor suppressor is mutated, deleted, or expressed at reduced levels in a high percentage of human prostate cancers (28, 29) including PTEN loss of heterozygosity in up to 20% of localized prostate cancers and more than 60% in advanced disease states.